TX-PLANVIEW
9.7.2020 16:05:11 CEST | Business Wire | Press release
Planview® today announced the acquisition of Aptage, a technology leader and pioneer in the application of Artificial Intelligence (AI) and Machine Learning (ML) to portfolio management and work management.
Aptage’s expertise in data science is combined with unique domain knowledge in the economics of development spanning Agile and project methodologies. The company’s technology and IP is focused on the application of AI/ML to enterprise software, offering customers early insights and visibility into anticipated value and delivery risk across traditional project management and agile methodologies. For Planview customers, this ultimately means more accurate project outcome forecasting, regardless of work methodologies and processes used to get work done.
“In today’s disruptive environment, the companies with early insights are the ones that can pivot more quickly to create competitive advantage,” said Greg Gilmore, CEO of Planview. “Aptage’s innovative AI/ML technology creates insights into project value and delivery risk, improving and strengthening the strategy to delivery pipeline. We’re excited to welcome Aptage into the Planview family and bring this expertise to our customers.”
“Aptage and Planview share a common vision for the future of AI/ML within portfolio management and work management,” said John Heintz, co-founder and CEO of Aptage. “We’re thrilled to be taking this next step together, expanding the reach of our technology and driving better outcomes for organizations.”
Founded in 2016, Aptage’s proprietary IP was designed to accommodate the small data characteristics of Agile and traditional projects to continuously learn, predict, and provide actionable advice throughout the strategy to delivery pipeline. The technology has been proven with early adopters and is ready to scale to the mainstream market with Planview.
John Heintz, co-founder and CEO, and Dr. Murray Cantor, co-founder and CTO, will be joining Planview, bringing extensive experience and unique expertise to the company. Heintz is a recognized thought leader in the Agile and Lean community with 20 years of hands-on experience, and will be joining to lead product management for AI/ML. Dr. Cantor joins Planview as the company’s Chief Data Scientist, a new role created in recognition of the momentum in data science and the application of AI/ML in enterprise software.
Planview will be embedding the Aptage AI/ML IP across the Planview product portfolio. We anticipate the Aptage technology being available to customers later this year. To learn more, visit: Planview.com .
Additional Resources:
- Aptage website
- Register for Planview Horizons – Sept 15-16, 2020
- Follow the Planview Blog
- Connect with Planview on Twitter , Facebook and LinkedIn
About Planview
Planview has one focus: enabling the transformation journey as organizations rewire strategy to delivery in today’s fast-paced, highly disruptive markets. Our solutions uniquely help organizations navigate this journey and accelerate on-strategy delivery at enterprise scale. Planview’s full spectrum of Portfolio Management and Work Management solutions create organizational focus on the strategic outcomes that matter and empower teams to deliver their best work, no matter how they work. The comprehensive Planview platform and enterprise success model enable customers to deliver innovative, competitive products, services, and customer experiences. Headquartered in Austin, Texas, Planview has more than 700 employees supporting 3,500 customers and 1 million users worldwide. For more information, visit: https://www.planview.com/ .
Planview and the Planview logo are registered trademarks of Planview, Inc. All other trademarks are property of their respective owners.
About Aptage
Aptage is a technology leader and pioneer in the application of Artificial Intelligence (AI) and Machine Learning (ML) to portfolio and work management, enabling companies to use their own data more intelligently through schedule, cost, and prioritization solutions. Companies using Agile, Waterfall, or hybrid frameworks have used Aptage to learn more from their project data and make informed business decisions based on AI advice. For more information, visit: https://get.aptage.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200709005606/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Even Realities Brings Classic Tortoiseshell Design to Smart Glasses with New Even G2 Brown 226.10.2026 15:00:00 CET | Press release
The new brown colorway pairs traditional eyewear craftsmanship with display-first technology, alongside Even G2 Clip (Polarized) and Even G2 Chain Even Realities, the company behind camera-free, display-first smart glasses, today introduced Brown 2, a new tortoiseshell-inspired colorway for Even G2, alongside two accessories: Even G2 Clip (Polarized) and the Even G2 Chain. Designed to bring the warmth and character of traditional tortoiseshell eyewear to smart glasses, Brown 2 features a newly developed material that carries its layered pattern throughout the frame rather than applying it as a surface finish. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026502782/en/ Even G2 Chain. Photo Credit: Even Realities Each frame is individually shaped, pressed, tumbled, and polished for 20 hours, creating subtle variations that make every pair unique. Brown 2 is also the lightest Even G2 design to date, while retaining the came
Incyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 202626.10.2026 14:45:00 CET | Press release
INCB161734 (KRAS G12D inhibitor) and INCA338901 (TGFβR2×PD-1 bispecific antibody) data reinforce ongoing and planned registrational trials, including DAWN-303 in pancreatic ductal adenocarcinoma (PDAC) and NEXERA-303 in colorectal cancer (CRC), respectivelyNew data evaluating INCB161734 in CRC highlight its clinical activity across KRAS G12D-mutated tumor types and support initiation of a Phase 3 study in second-line CRC planned for 2027INCB161734 and INCA33890 demonstrated manageable safety profiles in combination with standard-of-care (SoC) chemotherapiesNew collaborations with Bristol Myers Squibb and Synnovation in PDAC to evaluate INCB161734 in combination with navlimetostat, an MTA-cooperative PRMT5 inhibitor, and SNV1521, a PARP1 inhibitor, respectivelyThese results and additional updates will be presented at an analyst and investor event on Monday, October 26, 2026, from 7:30 – 9:00 p.m. CET (2:30 – 4:00 p.m. EDT) Incyte (Nasdaq:INCY) announced new results from its advancing on
Bending Spoons Completes the Acquisition of Miro26.10.2026 14:00:00 CET | Press release
Bending Spoons S.p.A. (NASDAQ: BSP) has completed the previously announced acquisition of Miro, the visual collaboration platform used by more than 250,000 organizations to brainstorm, plan, and build together. “Miro has built a strong business around a product that makes complex collaborative work feel simple,” said Luca Ferrari, Bending Spoons CEO and co-founder. “Miro’s versatility has made it useful across a broad range of industries and workflows, while creating a robust foundation for further expansion. We believe there’s significant potential to build on these strengths. We look forward to drawing on Bending Spoons’ technologies and expertise to make Miro even more useful to customers and support its continued growth.” “Teams depend on Miro for innovating, alignment, coordination, and decisioning, and that need is only growing,“ said Andrey Khusid, CEO and co-founder of Miro. “In Bending Spoons, Miro has an owner who invests for the long term and cares deeply about product quali
Dubai Culture Opens Registration for ISEA2026 Dubai26.10.2026 13:09:00 CET | Press release
Dubai Culture and Arts Authority (Dubai Culture) has opened registration for the 31st International Symposium on Electronic/Emerging Art (ISEA2026 Dubai), taking place from 6 to 15 November 2026 under the theme ‘ELYAH: Constellating Place, Data and Identity’. The symposium will be the largest edition to date, bringing together artists, researchers, and innovators from around the world to explore the intersection of art, science, and technology and exchange perspectives on the future of contemporary creative practice. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026652826/en/ Dubai Culture Opens Registration for ISEA2026 Dubai (Graphic: AETOSWire) The event supports Dubai Culture’s efforts to advance the digital arts ecosystem, deliver on its Digital Arts Roadmap objectives, and empower local talent. It also reinforces Dubai’s position as a global cultural reference, a leader in innovation, a driver of the creative econo
Agendia Unveils Clinical Validation of AI-Driven Digital Pathology Approach26.10.2026 13:00:00 CET | Press release
The investigational AI-driven digital assay demonstrated high concordance with MammaPrint results in the prospective RASTER cohort of 372 early-stage breast cancer patients with a median follow-up of 10.3 years Agendia, Inc., a leader in precision oncology for breast cancer, recently presented research introducing its investigational artificial intelligence (AI)-driven digital pathology approach for the MammaPrint®70-gene recurrence signature at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid. The podium presentation, delivered by co-founder and Chief Research Officer, Laura van ’t Veer, Ph.D., detailed the development and clinical validation of a deep learning pipeline that can infer MammaPrint (MP) risk categories directly from hematoxylin and eosin (H&E)-stained, whole-slide images (WSIs). The company also presented two additional posters highlighting data from the prospective, real-world FLEX Study (NCT03053193). “AI has been part of Agendia’s scientific fo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom